T type calcium channel antagonists - Pipeline Insight, 2022
This report can be delivered to the clients within 48 hours
DelveInsight’s, “T Type Calcium Channel Antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in T Type Calcium Channel Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
T Type Calcium Channel Antagonists: Overview
T-type calcium channels are low-voltage activated calcium channels. T-type calcium channels are predominantly found in neurons but have been found in other cells including cardiac myocytes, pacemaker cells, glial cells, fibroblasts, osteoblasts, retinal cells, and adrenocortical cells. These channels are known to play roles in the development, maintenance, and repair of these tissues but have also been implicated in disease when not properly regulated. T-type Ca2+ channel blockers are capable of interrupting certain pathological hypertrophic signaling pathways, including calcineurin-mediated nuclear factor of activated T cells–3 activation. Trimethadione (TMO) is a T-type calcium channel blocker approved by the FDA as an anticonvulsant for absence seizures.
Report Highlights
This segment of the T Type Calcium Channel Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
T Type Calcium Channel Antagonists Emerging Drugs
Further product details are provided in the report……..
T Type Calcium Channel Antagonists: Therapeutic Assessment
This segment of the report provides insights about the different T Type Calcium Channel Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
T Type Calcium Channel Antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses T Type Calcium Channel Antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging T Type Calcium Channel Antagonists drugs.
T Type Calcium Channel Antagonists Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “T Type Calcium Channel Antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in T Type Calcium Channel Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
T Type Calcium Channel Antagonists: Overview
T-type calcium channels are low-voltage activated calcium channels. T-type calcium channels are predominantly found in neurons but have been found in other cells including cardiac myocytes, pacemaker cells, glial cells, fibroblasts, osteoblasts, retinal cells, and adrenocortical cells. These channels are known to play roles in the development, maintenance, and repair of these tissues but have also been implicated in disease when not properly regulated. T-type Ca2+ channel blockers are capable of interrupting certain pathological hypertrophic signaling pathways, including calcineurin-mediated nuclear factor of activated T cells–3 activation. Trimethadione (TMO) is a T-type calcium channel blocker approved by the FDA as an anticonvulsant for absence seizures.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence T Type Calcium Channel Antagonists R&D. The therapies under development are focused on novel approaches for T Type Calcium Channel Antagonists.
This segment of the T Type Calcium Channel Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
T Type Calcium Channel Antagonists Emerging Drugs
- NBI 827104: Neurocrine Biosciences
- PRAX-944: Praxis Precision Medicines
Further product details are provided in the report……..
T Type Calcium Channel Antagonists: Therapeutic Assessment
This segment of the report provides insights about the different T Type Calcium Channel Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on T Type Calcium Channel Antagonists
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
T Type Calcium Channel Antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses T Type Calcium Channel Antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging T Type Calcium Channel Antagonists drugs.
T Type Calcium Channel Antagonists Report Insights
- T Type Calcium Channel Antagonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing T Type Calcium Channel Antagonists drugs?
- How many T Type Calcium Channel Antagonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for T Type Calcium Channel Antagonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the T Type Calcium Channel Antagonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for T Type Calcium Channel Antagonists and their status?
- What are the key designations that have been granted to the emerging drugs?
- Bial
- Synokem Pharmaceuticals
- Neurocrine Biosciences
- Praxis Precision Medicines
- Sihuan Pharmaceutical Holdings Group
- Cellix Bio
- Maruho
- DermaXon
- Eslicarbazepine acetate
- Benidipine/telmisartan
- NBI 827104
- PRAX-944
- KBP 5660 Sihuan Pharmaceutical Holdings Group
- CLX-CNS-04
- Research programme: pain therapeutics
- DX 416
Introduction
Executive Summary
T Type Calcium Channel Antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
T Type Calcium Channel Antagonists – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
T Type Calcium Channel Antagonists companies’ collaborations, Licensing, Acquisition -Deal Value Trends
T Type Calcium Channel Antagonists Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Benidipine/telmisartan: Synokem Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
NBI 827104: Neurocrine Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
KBP 5660: Sihuan Pharmaceutical Holdings Group
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
CLX-CNS-04: Cellix Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
T Type Calcium Channel Antagonists Key Companies
T Type Calcium Channel Antagonists Key Products
T Type Calcium Channel Antagonists- Unmet Needs
T Type Calcium Channel Antagonists- Market Drivers and Barriers
T Type Calcium Channel Antagonists- Future Perspectives and Conclusion
T Type Calcium Channel Antagonists Analyst Views
T Type Calcium Channel Antagonists Key Companies
Appendix
Executive Summary
T Type Calcium Channel Antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
T Type Calcium Channel Antagonists – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
T Type Calcium Channel Antagonists companies’ collaborations, Licensing, Acquisition -Deal Value Trends
T Type Calcium Channel Antagonists Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Benidipine/telmisartan: Synokem Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
NBI 827104: Neurocrine Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
KBP 5660: Sihuan Pharmaceutical Holdings Group
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
CLX-CNS-04: Cellix Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
T Type Calcium Channel Antagonists Key Companies
T Type Calcium Channel Antagonists Key Products
T Type Calcium Channel Antagonists- Unmet Needs
T Type Calcium Channel Antagonists- Market Drivers and Barriers
T Type Calcium Channel Antagonists- Future Perspectives and Conclusion
T Type Calcium Channel Antagonists Analyst Views
T Type Calcium Channel Antagonists Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for T Type Calcium Channel Antagonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for T Type Calcium Channel Antagonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for T Type Calcium Channel Antagonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for T Type Calcium Channel Antagonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
